0001428336-20-000004.txt : 20200123 0001428336-20-000004.hdr.sgml : 20200123 20200123161016 ACCESSION NUMBER: 0001428336-20-000004 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20200117 ITEM INFORMATION: Termination of a Material Definitive Agreement FILED AS OF DATE: 20200123 DATE AS OF CHANGE: 20200123 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HEALTHEQUITY, INC. CENTRAL INDEX KEY: 0001428336 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 0131 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36568 FILM NUMBER: 20542185 BUSINESS ADDRESS: STREET 1: 15 WEST SCENIC POINTE DRIVE STREET 2: SUITE 100 CITY: DRAPER STATE: UT ZIP: 84020 BUSINESS PHONE: 801-727-1000 MAIL ADDRESS: STREET 1: 15 WEST SCENIC POINTE DRIVE STREET 2: SUITE 100 CITY: DRAPER STATE: UT ZIP: 84020 FORMER COMPANY: FORMER CONFORMED NAME: HEALTHEQUITY INC DATE OF NAME CHANGE: 20080227 8-K 1 hqy-20200117.htm 8-K hqy-20200117
0001428336false00014283362020-01-172020-01-17

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

January 17, 2020

HEALTHEQUITY, INC.


Delaware
001-36568
52-2383166
(State or other jurisdiction of
incorporation or organization)
(Commission File Number)
(I.R.S. Employer
Identification Number)

15 West Scenic Pointe Drive
Suite 100
Draper, Utah 84020
(801) 727-1000

(Address, including Zip Code, and Telephone Number, including Area Code, of Registrant’s Principal Executive Offices)

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, par value $0.0001 per shareHQYThe NASDAQ Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). 
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐






Item 1.02 Termination of a Material Definitive Agreement.

On January 17, 2020, WageWorks, Inc. ("WageWorks"), a subsidiary of the HealthEquity, Inc., entered into a Lease Termination Agreement with Park Place Holdco, LLC (as successor in interest to Park Place Realty Holding Company, Inc.). Under the terms of the Lease Termination Agreement, the office lease (the "Terminated Lease") dated April 10, 2014 by and between WageWorks and Park Place Realty Holding Company, Inc. was terminated, effective as of March 7, 2020. Under the terms of the Terminated Lease, WageWorks leased approximately 37,937 rentable square feet in San Mateo, California. In connection with the Lease Termination Agreement, WageWorks agreed to pay a termination fee in the amount of $1.5 million.

This current report on Form 8-K summarizes the material provisions of the Lease Termination Agreement, although the Lease Termination Agreement is subject to other customary terms and conditions. This summary is qualified in its entirety by reference to the full text of the Lease Termination Agreement, which is included in Exhibit 10.1 to this Form 8-K.

(d) Exhibits

Exhibit No. Description





SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HEALTHEQUITY, INC.
Date: January 23, 2020By:/s/ Delano Ladd
Name:Delano Ladd
Title:EVP, General Counsel and Secretary


 EX-10.1 2 a101sf-1131970xv5x1100.htm EX-10.1 Document


LEASE TERMINATION AGREEMENT
This Lease Termination Agreement (this "Agreement") is entered into as of January 17, 2020, by and between PARK PLACE HOLDCO LLC, a Delaware limited liability company ("Landlord"), and WAGEWORKS, INC., a Delaware corporation ("Tenant").
r e c i t a l s :
A.Park Place Realty Holding Company, Inc., a Delaware corporation (as predecessor in interest to Landlord) and Tenant are parties to that certain Office Lease dated as of April 10, 2014 (the "Lease"), whereby Landlord leases to Tenant that certain space (the "Premises") consisting of approximately 37,937 rentable square feet, commonly known as Suite 400, and located on the fourth (4th) floor of that certain building (the "Building") located at 1100 Park Place, San Mateo, California.
B.Subject to and in accordance with this Agreement, Landlord and Tenant desire to enter into this Agreement in order to terminate the Lease and to release one another from their respective obligations thereunder, except as otherwise provided herein.
a g r e e m e n t :
NOW, THEREFORE, in consideration of the foregoing recitals and the conditions and the covenants hereinafter contained, and for other consideration hereinafter set forth, the receipt and sufficiency of which are hereby acknowledged, Landlord and Tenant hereby agree as follows.
1.Defined Terms. All terms defined in the Lease when used herein shall have the same meaning as is given such terms in the Lease unless expressly superseded by the terms of this Agreement.
2.Effectiveness of this Lease Termination Agreement. Landlord and Tenant hereby acknowledge and agree that, notwithstanding the full execution and delivery of this Agreement by Landlord and Tenant, this Agreement is expressly conditioned upon the full execution and delivery of a lease agreement (the "Third-Party Lease") by Landlord and Medallia, Inc., a Delaware corporation (the "Third Party Tenant") (the terms and conditions of which Third-Party Lease shall be acceptable to Landlord in its sole and absolute discretion) with respect to a lease of the Premises effective following the "Termination Date," as defined in Section 3 (the "Condition Precedent"). Landlord shall have no liability whatsoever to Tenant relating to or arising from Landlord’s inability or failure to cause all or any portion of the Condition Precedent to be satisfied. The Lease shall remain unmodified and in full force and effect unless and until such time as the Condition Precedent is satisfied or waived. Landlord shall notify Tenant in writing promptly once the Condition Precedent has been satisfied.
3.Termination of the Lease. Landlord and Tenant hereby agree that, conditioned upon the performance by the parties of the provisions of this Agreement, the Lease shall terminate and be of no further force or effect as of 11:59 P.M. Pacific Standard Time on March 7, 2020 (the "Termination Date").
4.Termination Payment. In consideration of Landlord's agreement to terminate the Lease prior to its scheduled expiration date, Tenant shall pay Landlord a termination fee in the amount of One Million Five Hundred Thousand and No/100 Dollars ($1,500,000.00) (the "Termination Payment"). The Termination Payment shall be due and payable by Tenant within three (3) business days following mutual execution and delivery of this Agreement. In the event the Condition Precedent is not satisfied within thirty (30) days of the Termination Date, then the amount of the Termination Payment shall be applied






monthly as a credit against Rent for the following months until the entirety of the Termination Payment has been returned to Tenant.
5.Surrender of Premises. Subject to the satisfaction of the Condition Precedent, Tenant hereby agrees to vacate the Premises and surrender and deliver exclusive possession of the Premises to Landlord on or before the Termination Date in accordance with the provisions of the Lease pertaining to the vacation and surrender of the Premises by Tenant at the end of the Lease Term, including, without limitation, Articles 8 and 15 of the Lease. Except as otherwise agreed upon in writing by Tenant and Third Party Tenant (the "Written Agreement", a copy of which shall be provided by Tenant to Landlord prior to the Termination Date), on or before the Termination Date, Tenant shall, at Tenant’s sole cost and expense, remove or cause to be removed from the Premises any and all of Tenant's personal property, and such similar articles of any other persons claiming under Tenant, as well as any improvements and/or alterations required to be removed by Tenant under the terms of the Lease upon the expiration or earlier termination of the Lease, including, without limitation, the Exterior Sign from the Building (as further provided in Section 23.5 of the Lease), but not including the furniture, fixtures and equipment ("FF&E") set forth on Exhibit A so long as Tenant provides Landlord with the Written Agreement as provided above. Tenant shall deliver the Premises to Landlord in a broom-clean condition. Tenant shall immediately repair at its own expense all damage to the Premises and the Building resulting from any such removal. If Tenant fails to complete such removal and/or repair any damage caused by such removal, Landlord may (but shall not be obligated to) do so and may charge the reasonable and actual cost thereof to Tenant. In the event Tenant fails to surrender the Premises by the Termination Date in the condition required hereunder, then the provisions of the Lease, including, without, limitation, Article 16 of the Lease, shall apply, provided that Tenant's continued occupancy of the Premises after the Termination Date shall be deemed a tenancy-at-sufferance.
6.Release of Liability. Except with respect to all obligations set forth in the Lease that survive the termination of the Lease, including, without limitation, Tenant’s indemnity obligations, and except as otherwise provided in this Agreement, including, without limitation, Tenant's obligation to pay the Termination Payment pursuant to Section 4 above, and conditioned on the performance by the parties of the provisions of this Agreement, effective as of the Termination Date:
(a)the parties shall be fully and unconditionally released and discharged from their respective obligations arising from or in connection with the provisions of the Lease; and
(b)this Agreement shall fully and finally settle all demands, charges, claims, accounts or causes of action of any nature, including, without limitation, both known and unknown claims and causes of action that may arise out of or in connection with the obligations of the parties under the Lease.
Each of the parties expressly waives the provisions of California Civil Code Section 1542, which provides:
"A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY."
Each party acknowledges that it has received the advice of legal counsel with respect to the aforementioned waiver and understands the terms thereof.
7.Representations of Tenant. Tenant represents and warrants to Landlord that (a) Tenant has not heretofore assigned all or any portion of its interest in the Lease or sublet any portion of the

-2-




Premises; (b) no person, firm or entity has any right, title or interest in the Lease; (c) as of the Termination Date, no person, firm or entity shall have any right, title or interest in the Lease or the Premises; (d) Tenant has not caused or permitted any release or disposal on, under, within or from the Premises of any hazardous or toxic materials and, as of the Termination Date, Tenant shall have properly removed from the Premises all such hazardous and/or toxic materials stored or used by or on behalf of Tenant within the Premises; (e) Tenant has not violated any applicable laws, statutes, ordinances, regulations, rules and other governmental requirements with respect to Tenant's use or occupancy of the Premises, which violation shall not have been remedied by Tenant on or before the Termination Date; (f) Tenant has the full right, legal power and actual authority to enter into this Agreement and to terminate the Lease; and (g) as of the date hereof, there are no, and as of the Termination Date, there shall not be any, mechanic's liens or other liens encumbering all or any portion of the Premises, by virtue of any act or omission on the part of Tenant, its predecessors, contractors, agents, employees, successors or assigns. Notwithstanding the termination of the Lease and the release of liability, as provided herein, the representations and warranties set forth in this Section 7 shall survive the termination of the Lease and Tenant shall be liable to Landlord for any inaccuracy or any breach thereof.
8.Continuing Liability. Notwithstanding the termination of the Lease and the release of liability provided for herein, Tenant shall remain liable, with respect to the period of its tenancy prior to the Termination Date, for the performance of all of its obligations under the Lease (including, without limitation, Tenant’s payment of reconciliation of Tenant's Share of Building Direct Expenses with respect to calendar year 2019; with respect to calendar year 2020, the parties hereby agree that no further reconciliation shall be required for payments made by Tenant in connection with Tenant's Share of Building Direct Expenses, and such payments for calendar year 2020 shall be deemed sufficient when made) and Landlord shall have all the rights and remedies with respect to such obligations as set forth in the Lease.
9.Entire Agreement. It is understood and acknowledged that there are no oral agreements among the parties hereto affecting this Agreement and this Agreement supersedes and cancels any and all previous negotiations, arrangements, agreements and understandings, if any, among the parties hereto, relating in any manner to the termination of the Lease and the release of liability, as provided herein, and none thereof shall be used to interpret or construe this Agreement. This Agreement contains all of the terms, covenants, conditions, warranties and agreements of the parties relating in any manner to the termination of the Lease and the release of liability, as provided herein, shall be considered to be the only agreement among the parties hereto and their representatives and agents relating in any manner to the termination of the Lease and the release of liability, and none of the terms, covenants, conditions or provisions of this Agreement can be modified, deleted or added to except in writing signed by the parties hereto. All negotiations and oral agreements acceptable to both parties have been merged into and are included herein. There are no other representations or warranties among the parties, and all reliance with respect to representations is based totally upon the representations and agreements contained in this Agreement.
10.Attorneys' Fees. Should any dispute arise between the parties hereto or their legal representatives, successors and assigns concerning any provision of this Agreement or the rights and duties of any person in relation thereto, the party prevailing in such dispute shall be entitled, in addition to such other relief that may be granted, to recover reasonable attorneys' fees and legal costs in connection with such dispute.
11.Authority. If Tenant is a corporation, trust, limited liability company or partnership, each individual executing this Agreement on behalf of Tenant hereby represents and warrants that Tenant is a duly formed and existing entity qualified to do business in California and that Tenant has full right and authority to execute and deliver this Agreement and that each person signing on behalf of Tenant is authorized to do so. In such event, Tenant shall, within ten (10) days after written request by Landlord, deliver to Landlord satisfactory evidence of such (i) authority, (ii) good standing in Tenant's state of formation and (iii) qualification to do business in California.

-3-




12.Conflict; No Further Modification. In the event of any conflict between the terms and conditions of the Lease and the terms and conditions of this Agreement, the terms and conditions of this Agreement shall prevail. Except as specifically set forth in this Agreement, all of the terms and conditions of the Lease shall remain unmodified and in full force and effect.
13.Broker. Tenant shall indemnify, defend and hold Landlord harmless from and against any and all claims by any real estate broker or salesman for a commission, finder’s fee or other compensation alleged to be owing on account of Tenant's dealings with such party as a result of Tenant’s entering into this Agreement.
[Signatures appear on the following page]

-4-




IN WITNESS WHEREOF, Landlord and Tenant have executed this Agreement as of the day and year first above written.

Landlord:Tenant:
PARK PLACE HOLDCO LLC, a Delaware limited liability companyWAGEWORKS, INC., a Delaware corporation
By:/s/ Karen WilbrechtBy:/s/ Darcy Mott
Name:Karen WilbrechtName:Darcy Mott
Title:Vice PresidentTitle:EVP & CFO







 EX-101.SCH 3 hqy-20200117.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 hqy-20200117_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 hqy-20200117_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 hqy-20200117_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Type Document Type Cover page. Cover page. City Area Code City Area Code Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Entity File Number Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, City or Town Entity Address, City or Town Security Exchange Name Security Exchange Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Address Line Two Entity Address, Address Line Two Entity Registrant Name Entity Registrant Name Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Address, Address Line One Entity Address, Address Line One Entity Central Index Key Entity Central Index Key Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Trading Symbol Trading Symbol Entity Address, State or Province Entity Address, State or Province Title of 12(b) Security Title of 12(b) Security Pre-commencement Tender Offer Pre-commencement Tender Offer EX-101.PRE 7 hqy-20200117_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 8 hqy-20200117_htm.xml IDEA: XBRL DOCUMENT 0001428336 2020-01-17 2020-01-17 0001428336 false 8-K 2020-01-17 HEALTHEQUITY, INC. DE 001-36568 52-2383166 15 West Scenic Pointe Drive Suite 100 Draper UT 84020 801 727-1000 false false false false Common stock, par value $0.0001 per share HQY NASDAQ false XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3.a.u2 html 1 97 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Page Sheet http://healthequity.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports hqy-20200117.htm a101sf-1131970xv5x1100.htm hqy-20200117.xsd hqy-20200117_cal.xml hqy-20200117_def.xml hqy-20200117_lab.xml hqy-20200117_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true true JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "hqy-20200117.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "hqy-20200117_cal.xml" ] }, "definitionLink": { "local": [ "hqy-20200117_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "hqy-20200117.htm" ] }, "labelLink": { "local": [ "hqy-20200117_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "hqy-20200117_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "hqy-20200117.xsd" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 97, "memberCustom": 0, "memberStandard": 0, "nsprefix": "hqy", "nsuri": "http://healthequity.com/20200117", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20200117.htm", "contextRef": "ibf833187aab24fcfb5609e0e42a8e7c7_D20200117-20200117", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://healthequity.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20200117.htm", "contextRef": "ibf833187aab24fcfb5609e0e42a8e7c7_D20200117-20200117", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover page.", "terseLabel": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } EXCEL 14 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 15 R1.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Cover Page
Jan. 17, 2020
Cover page.  
Document Type 8-K
Document Period End Date Jan. 17, 2020
Entity File Number 001-36568
Entity Registrant Name HEALTHEQUITY, INC.
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 52-2383166
Entity Address, Address Line One 15 West Scenic Pointe Drive
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Draper
Entity Address, State or Province UT
Entity Address, Postal Zip Code 84020
City Area Code 801
Local Phone Number 727-1000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.0001 per share
Trading Symbol HQY
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001428336
Amendment Flag false
ZIP 16 0001428336-20-000004-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001428336-20-000004-xbrl.zip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end